Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

Get CLEATUSFree Trial

Get CLEATUSFree Trial

Search

Top

3M Company 3M Center, Building 224-2S-25 SAINT PAUL MN 55144 USA

UEI: SLED_92FB547AB0D5330E

3M Company 3M Center, Building 224-2S-25 SAINT PAUL MN 55144 USA is a federal contractor, registered under UEI SLED_92FB547AB0D5330E. It has been awarded $5,904,904 across 1 federal contract. Primary work spans Research and Development in Biotechnology.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_92FB547AB0D5330E

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

$5.9M100%

Awards by NAICS

541711 - Research and Development in Biotechnology$5.9M100%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in 3M Company 3M Center, Building 224-2S-25 SAINT PAUL MN 55144 USA's top NAICS codes and agencies

Clinical Trial Design and Efficacy Data GenerationThe contract calls for the design and execution of clinical trials aimed at evaluating the safety, wound closure, infection control, and functional regeneration outcomes of medical interventions in patients with burn and trauma injuries. The work requires rigorous scientific methodology to generate robust efficacy data that supports regulatory and clinical adoption, with a focus on measurable endpoints related to tissue recovery and patient outcomes. The trials must be conducted in accordance with established clinical standards and are intended to provide evidence of therapeutic effectiveness under real-world conditions. This is a subcontract under the Aspr Administration for Strategic Preparedness and Response, part of the Department of Health and Human Services, with a solicitation posted on July 28, 2026, and a response deadline of August 28, 2026. The work is classified under NAICS code 541711, indicating research and development in the life sciences. The performance location is designated with a zip code of 77416, though no specific city or state is provided, and no point of contact details are listed. The contract does not include a set-aside designation, and all eligible entities may respond, with emphasis placed on technical capability, trial design expertise, and experience in trauma and burn clinical research.

Aspr Administration For Strategic Preparedness And Response

POSTED

DEADLINE

Induced Pluripotent Stem Cell (iPSC) Reprogramming ServicesThe contract entails the reprogramming of human articular chondrocytes and bone marrow cells into induced pluripotent stem cells using Sendai virus technology, with full support for culture expansion and cryopreservation of the resulting iPSCs. This subcontract is part of a research initiative led by the Department of Veterans Affairs through Rpo East, focused on advancing regenerative medicine techniques through advanced cellular reprogramming methods. The work requires precise adherence to protocols ensuring high efficiency, safety, and scalability of iPSC generation while maintaining cell viability and pluripotency throughout the process. The solicitation is open for responses until August 6, 2026, and falls under NAICS code 541711, indicating it is for research and development in the biological sciences. The agreement is structured as a subcontract, suggesting it will be awarded to a specialized contractor with expertise in stem cell biology and virology-based reprogramming. Performance is expected to meet rigorous quality standards for cellular products intended for potential therapeutic or diagnostic applications, with an emphasis on reproducibility and documentation. All deliverables must include verified iPSC lines archived through cryopreservation, ready for downstream use in future studies or clinical translation.

Rpo East (36C24E)

POSTED

DEADLINE

Emerging Animal & Zoonotic Disease Diagnostics Research

Sci Technology Acq Division

POSTED

DEADLINE

Preclinical Animal Studies for Neurofibromatosis ResearchThe contract seeks to conduct preclinical in vivo studies using genetically engineered mouse models or alternative animal models of neurofibromatosis to assess the efficacy of therapeutic interventions, track tumor progression, and investigate underlying biological mechanisms. The work requires advanced expertise in animal modeling, tumor biology, and preclinical drug evaluation, with a focus on generating robust, reproducible data to support future clinical translation. All studies must be conducted in accordance with established ethical and scientific standards for animal research, with detailed documentation of methodologies, outcomes, and adverse events. This subcontract is issued under the Defense Health Agency Contracting Activity and falls under NAICS code 541711, indicating it supports research and development in the physical, engineering, and life sciences. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is open to qualified entities capable of executing complex preclinical studies. While the place of performance and point of contact details are unspecified, successful proposers must demonstrate capacity to manage animal facilities, comply with regulatory requirements, and deliver high-quality, timely results in support of neurofibromatosis research objectives under the Department of Defense.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 1 month ago

DEADLINE

in about 2 months

Collaborative Biomedical Research ExecutionThis contract enables a collaborative biomedical research effort focused on neurofibromatosis, requiring coordinated hypothesis-driven investigations led by an Initiating Principal Investigator and a Partnering Principal Investigator. The work encompasses the design of experiments, generation of empirical data, and rigorous milestone-based progress reporting to ensure scientific rigor and accountability. The project is structured as a subcontract under the Defense Health Agency Contracting Activity, falling under the NAICS code for research and development in the physical, engineering, and life sciences, and is intended to advance understanding of neurofibromatosis through integrated scientific contributions. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is managed by the Department of Defense through its health research infrastructure. While no set-aside provisions or specific location details are provided, the emphasis is firmly on outcome-driven research with clearly defined deliverables tied to research milestones. The effort requires close alignment between the two principal investigators to ensure cohesive experimental planning, data integrity, and timely reporting, reflecting a strategic investment in translational medical science with potential implications for defense-relevant health conditions.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 1 month ago

DEADLINE

in about 2 months

Collaborative Research Partnership (Partnering PI Option)This contract establishes a collaborative research partnership where a Partnering Principal Investigator from an external institution will co-lead the research effort alongside the primary team, sharing equal responsibility for scientific direction, project management, and deliverables. Funding is jointly allocated between the participating institutions, ensuring aligned resources and mutual accountability for outcomes, with the work focused on health-related research under the Defense Health Agency Contracting Activity. The initiative falls under NAICS code 541711, indicating it is within the scientific research and development sector, and is structured as a subcontract to support integrated, multi-institutional innovation. The opportunity was posted on June 18, 2026, with a deadline for responses set for September 28, 2026, providing potential partners a defined window to submit proposals. The partnership is expected to be conducted in alignment with the mission of the Department of Defense, addressing critical health priorities through joint scientific leadership. There is no set-aside designation specified, meaning eligibility is open to qualified institutions regardless of size or status, and no specific location is designated for performance, allowing flexibility in where the research activities are carried out as long as the objectives are met collaboratively.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 1 month ago

DEADLINE

in about 2 months

Kidney Cancer Clinical Research ExecutionThe contract titled Kidney Cancer Clinical Research Execution aims to advance clinical and translational research focused on kidney cancer through comprehensive scientific activities including study design, patient data collection, biomarker analysis, and therapeutic development. The work is intended to support the development of innovative treatments and diagnostic strategies by integrating clinical observations with laboratory research, ensuring findings are rapidly translated into improved patient outcomes. The project requires expertise in oncology research methodologies, rigorous data management, and interdisciplinary collaboration to address critical gaps in kidney cancer understanding and care. This subcontract is issued by the Defense Health Agency Contracting Activity under the Department of Defense and falls under NAICS code 541711, indicating it is related to research and development in the life sciences. The opportunity was posted on June 18, 2026, with a response deadline of September 28, 2026, providing potential applicants approximately three months to prepare and submit proposals. The place of performance and specific office address details are not specified, suggesting flexibility in location but requiring proposers to align with the overarching objectives of the Department of Defense’s medical research priorities. All work must demonstrate scientific excellence, feasibility, and direct relevance to advancing kidney cancer therapeutics within a clinical context.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 1 month ago

DEADLINE

in about 2 months

Clinical Trial Design and Biostatistical SupportThe contract seeks specialized expertise to support clinical trial design and biostatistical analysis for orthopaedic trauma research funded by the Department of Defense, specifically under the U.S. Army Medical Research and Acquisition Activity. The work involves developing robust clinical trial methodologies, crafting statistical analysis plans, performing power analyses to ensure adequate sample sizes, and establishing data monitoring frameworks to ensure trial integrity and compliance with regulatory standards. Support must be tailored to the unique challenges of military-relevant trauma studies, including patient populations, deployment-related injuries, and the operational constraints of DoD medical settings. The opportunity is structured as a subcontract with a NAICS code of 541711, indicating it falls under research and development in the physical, engineering, and life sciences. The solicitation was posted on June 17, 2026, and responses are due by November 18, 2026. Performance is expected to occur within the broader DoD infrastructure, though no specific location is designated. There is no set-aside classification specified, and the contract is open to qualified entities capable of delivering high-level biostatistical and clinical trial methodological support in a defense medical research context.

Department Of The Army -- Usamraa

POSTED

about 1 month ago

DEADLINE

Preclinical Biomedical Research on Traumatic Orthopaedic InjuriesThis contract requires the conduct of preclinical biomedical research focused on bone healing, tissue regeneration, and orthopaedic trauma models using animal systems, with the goal of advancing medical solutions aligned with military needs. The work involves designing controlled experiments, collecting longitudinal data on injury response and recovery, and performing rigorous statistical and biological analysis to evaluate therapeutic interventions. All research must be tailored to simulate combat-related orthopaedic injuries and produce actionable insights applicable to field medical care and soldier recovery protocols. The effort is structured as a subcontract under the Department of the Army through USAMRAA, with a solicitation posted on June 17, 2026, and a response deadline of November 18, 2026. The project falls under NAICS code 541711 for research and development in the physical, engineering, and life sciences. Performance location and point of contact details are not specified, but the research must be executed in facilities capable of supporting high-standard animal modeling and biomechanical analysis. The ultimate objective is to generate validated preclinical data to inform the development of next-generation treatments for traumatic injuries sustained in military operations.

Department Of The Army -- Usamraa

POSTED

about 1 month ago

DEADLINE

Nanobody-Drug Conjugate Systems DevelopmentThe contract pertains to the licensing of the NanoFET platform to develop targeted nanobody-drug conjugates for the precision delivery of therapeutics using a modular scaffold designed to enhance specificity and efficiency in therapeutic distribution. This subcontract, issued by the Department of Energy through its contractor Triad, enables the recipient to leverage the proprietary NanoFET technology for advancing next-generation drug delivery systems with a focus on oncology and other targeted disease treatments. The project is centered in Los Alamos, New Mexico, with a response deadline of December 18, 2026, and falls under the NAICS code 541711 for research and development in biotechnology. The modular scaffold allows for customizable conjugation of nanobodies with therapeutic payloads, facilitating high-affinity targeting of disease markers while minimizing off-target effects. The agreement emphasizes technological innovation and the translation of advanced nanoscale platforms into clinically viable delivery systems.

Triad - DOE Contractor

POSTED

about 1 month ago

DEADLINE

Infectious Disease Vaccine DevelopmentThe contract involves licensing the NanoFET platform to enable rapid-response vaccine development against viral and bacterial pathogens, leveraging its unique adjuvant-free immune activation and modular antigen integration capabilities. This technology allows for swift adaptation to emerging infectious threats by streamlining the design and production of vaccines without relying on traditional immune-stimulating additives, significantly reducing development timelines and enhancing safety profiles. The work is structured as a subcontract under the Department of Energy, with performance centered at Los Alamos, New Mexico, and is targeted toward advancing national defense and public health preparedness through next-generation vaccine platforms. The opportunity is open for proposals until December 18, 2026, and falls under NAICS code 541711, indicating it targets research and development in the physical, engineering, and life sciences. The contracting entity is Triad, the DOE Contractor, and the initiative aligns with broader federal efforts to build resilient, scalable biodefense capabilities. Participants must demonstrate technical proficiency in the NanoFET platform, experience in infectious disease vaccine design, and the capacity to execute rapid development cycles under strict timelines. Success in this effort will contribute directly to scalable, next-generation immunization technologies capable of addressing current and future biological threats.

Triad - DOE Contractor

POSTED

about 1 month ago

DEADLINE

Modular Cancer Immunotherapy DevelopmentThe contract entails the license and development of the NanoFET platform for the creation of targeted cancer immunotherapies, leveraging its modular scaffold to deliver tumor-specific antigens and immune stimulators in a precise and effective manner. The work is focused on advancing next-generation immunotherapeutic approaches by engineering the platform to enhance immune recognition and response against cancer cells, with the goal of improving therapeutic outcomes and reducing off-target effects. The project requires collaboration to optimize the platform’s design, validate its efficacy in preclinical models, and prepare for subsequent clinical translation, all grounded in cutting-edge nanotechnology and immunological science. The contract is a subcontract under the Department of Energy, with performance centered in Los Alamos, New Mexico, 87545, and is classified under NAICS code 541711 for research and development in the physical, engineering, and life sciences. The solicitation was posted on June 17, 2026, with a response deadline of December 18, 2026, indicating a strategic timeline for proposal submission and evaluation. While details on set-aside status and point of contact are not provided, the project is positioned to align with national priorities in advanced biomedical innovation and cancer treatment, leveraging federal research infrastructure and expertise to drive transformative therapeutic solutions.

Triad - DOE Contractor

POSTED

about 1 month ago

DEADLINE

Antibody Development & LicensingThe contract involves the development, validation, and commercialization of monoclonal antibodies that specifically target bacterial membrane lipids. This work utilizes a nanodisc platform, which serves either as an immunogen or a screening tool, to enhance the effectiveness of antibody generation and assessment. The effort is positioned as a subcontract under the Department of Energy's Triad contractor, emphasizing a focus on innovative biotechnological approaches within a government research context. Work will be performed in Los Alamos, with the solicitation posted in mid-2026 and a response deadline toward the end of that year. The contract falls under NAICS code 541711, indicating its alignment with research and development in the physical, engineering, and life sciences. Although specific organizational and contact details are not provided, the contract is geared toward advancing antibody technologies through a combination of advanced immunological platforms and commercial application strategies.

Triad - DOE Contractor

POSTED

about 2 months ago

DEADLINE

Preclinical Research & Immunogenicity TestingThe contract involves the execution of binding assays, immune stimulation studies, and antigen identification leveraging the nanodisc platform, aimed at advancing vaccine or therapeutic development. This subcontract, titled "Preclinical Research & Immunogenicity Testing," is to support work primarily focused on preclinical stages of research, targeting immune responses and antigen characterization to facilitate the creation of effective medical interventions. Issued by the Department of Energy through its contractor Triad, the work is to be performed in Los Alamos, with a deadline for responses by mid-December 2026. Classified under NAICS code 541711, which pertains to research and development in biotechnology, the contract does not specify any particular set-aside requirements or organization type constraints. The research efforts under this agreement are expected to play a critical role in underpinning DOE-supported vaccine and therapeutic programs, emphasizing innovative assay platforms like nanodiscs to enhance scientific understanding and product development.

Triad - DOE Contractor

POSTED

about 2 months ago

DEADLINE

High-Throughput Serology Assay DevelopmentThe contract requires the design, validation, and delivery of a high-throughput serology platform intended to match or surpass the performance of the current hemagglutination inhibition (HAI) assay used for influenza surveillance. The platform must be scalable and robust enough to support large-scale, rapid serological testing, ensuring accurate and consistent data collection for public health monitoring. Development must adhere to stringent performance benchmarks, with a focus on improving throughput, precision, and reproducibility across diverse influenza strains and sample types. This is a subcontract under the Department of Defense’s FA9000 AFGPO program, with performance centered at DWG. The North American Industry Classification System code 541711 indicates it falls under research and development in the physical, engineering, and life sciences. The solicitation was posted on June 15, 2026, and the work is expected to advance the DoD’s capability in infectious disease surveillance by replacing aging laboratory methods with a next-generation automated system. While no set-aside or point of contact details are provided, the project’s success is critical to maintaining national-level preparedness for seasonal and pandemic influenza threats.

FA9000 Af Naf Po

POSTED

about 2 months ago

DEADLINE

Engineering & Scientific Research SupportThe contract entails providing engineering analysis, research and development, and technical support specifically focused on F-15 aircraft systems, encompassing avionics, propulsion, and weapons integration. The work involves activities such as modeling, simulation, and the formulation of test plans to support enhancements and maintenance of these complex systems. Issued by the Department of Defense under the NAICS code 541711, this subcontract titled "Engineering & Scientific Research Support" is designed to advance the technical capabilities and reliability of the F-15 platform. While certain logistical details like the exact place of performance and point of contact are not specified, the contract underscores a commitment to rigorous scientific and engineering efforts to ensure mission readiness and technological superiority for this key military asset.

FA8622 Aflcmc Azs Epass

POSTED

about 2 months ago

DEADLINE

Biomanufacturing Process DevelopmentThis contract focuses on the development of biomanufacturing processes to support scalable biological systems aimed at advancing medical countermeasures, synthetic biology, and bio-based materials specifically for defense applications. It is a subcontract opportunity issued by the Department of the Army under the Department of Defense, targeting expertise in process development within these cutting-edge biological fields to enhance capabilities in defense-related biotechnologies. The solicitation was posted on June 8, 2026, and interested parties must submit their responses by August 11, 2026. Categorized under the NAICS code 541711, which pertains to research and development in physical, engineering, and life sciences, this contract does not specify set-aside provisions or particular organization types. While precise performance locations and points of contact are not disclosed, the emphasis is clearly on advancing scalable and innovative biomanufacturing methods that will support defense objectives through the integration of synthetic biology and bio-based materials.

Department Of The Army -- Materiel Command

POSTED

about 2 months ago

DEADLINE

Non-Optical Signal Integration (Magnetic/Focused Ultrasound)The contract focuses on the development and integration of protein domains with magnetic fields or focused ultrasound techniques to enable remote, real-time control of cellular functions. The key objectives emphasize ensuring that these modulation methods are biologically compatible, minimizing any off-target effects that could interfere with cellular processes. This initiative aims to advance non-optical signal integration technologies with applications potentially valuable to biomedical and defense sectors. Issued by the Defense Advanced Research Projects Agency under the Department of Defense, the work is categorized under NAICS code 541711, which pertains to research and development in the physical, engineering, and life sciences. The contract is a subcontract opportunity with a response deadline set for December 8, 2026. Although location specifics and points of contact were not provided, the project aligns with DARPA’s goals of pioneering innovative and high-impact research solutions.

Defense Advanced Research Projects Agcy

POSTED

about 2 months ago

DEADLINE